GlassScriptPhysician profile
Rebecca M Bianco
NPI 1073218343
$7,637.52
in general payments reported to CMS, 2019-2025
34 companies · $2,225 in 2025
The $2,225 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,273 · 2024: $3,139 · 2025: $2,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,583 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,582.53 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,999.63 | 2023-2025 | |
| Lundbeck LLC | $753.25 | 2023-2025 | Vyepti, Rexulti |
| Harmony Biosciences LLC | $716.33 | 2023-2025 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $356.81 | 2023-2025 | Hyqvia |
| Lilly USA, LLC | $318.14 | 2023-2025 | Emgality, Kisunla, Zepbound |
| Neurocrine Biosciences, INC. | $316.19 | 2023-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $230.17 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $199.90 | 2024-2025 | Dysport |
| Axsome Therapeutics, INC. | $169.66 | 2023-2025 | Symbravo, Sunosi |
| Octapharma USA, INC. | $165.48 | 2024 | Panzyga |
| Merz Pharmaceuticals, LLC | $161.73 | 2023-2025 | Xeomin, Ampyra, Inbrija |
| Ucb, INC. | $126.42 | 2023-2025 | Rystiggo, Fintepla |
| Sk Life Science, INC. | $125.18 | 2024-2025 | |
| Csl Behring | $116.07 | 2023 | Hizentra |
| Amneal Pharmaceuticals LLC | $107.91 | 2023-2025 | Crexont, Rytary |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $94.51 | 2023-2024 | Nourianz |
| Otsuka America Pharmaceutical, INC. | $88.38 | 2024-2025 | Rexulti, Nuedexta |
| Grifols USA, LLC | $82.57 | 2023-2025 | Gamunex-C |
| Zoll Respicardia, INC. | $69.59 | 2024 | Remede System |
| Jazz Pharmaceuticals INC. | $54.42 | 2023-2024 | Xywav |
| Tonix Medicines, INC. | $52.09 | 2024-2025 | Zembrace Symtouch |
| Medtronic, INC. | $51.22 | 2024 | Percept PC Brainsense |
| Astrazeneca Pharmaceuticals LP | $40.44 | 2023 | |
| Protega Pharmaceutials INC | $34.29 | 2024 | Roxybond |
| Inspire Medical Systems, INC. | $28.09 | 2024 | Inspire |
| Azurity Pharmaceuticals, INC. | $27.79 | 2024-2025 | Horizant |
| Tanabe Pharma America, INC. | $27.41 | 2024 | |
| Microtransponder, INC. | $25.44 | 2024 | |
| Eisai INC. | $23.37 | 2024 | |
| Argenx US, INC. | $22.25 | 2023 | Vyvgart Hytrulo |
| Averitas Pharma INC. | $19.85 | 2025 | Qutenza |
| Acadia Pharmaceuticals INC | $17.87 | 2024 | Nuplazid |
| Merck Sharp & Dohme LLC | $15.07 | 2023 | Belsomra |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Bianco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.